仿制与创新门冬酰胺酶制剂活性比较及儿科白血病监测回顾分析
该研究比较了印度九种仿制L-门冬酰胺酶与创新药在儿童急性淋巴细胞白血病诱导治疗中的质量。通过测定给药后72小时谷浓度活性,发现仿制药达标率低至16.7%~84.9%,而创新药全部高于50 IU/L,提示仿制药质量存在严重临床隐患,需治疗药物监测与剂量调整。
要点
- 仿制L-门冬酰胺酶达标率低至16.7%~84.9%,创新药全部达标
- 体外活性仅为标示量的71.4%~74.6%,创新药为93.5%
- 建议在监管改善前采用剂量调整策略联合治疗药物监测
核心结论
- 仿制L-门冬酰胺酶活性低于创新药,引发对其质量的严重临床担忧。
- 在监管质量提升前,应考虑剂量适应策略联合治疗药物监测。
研究设计与样本
- 研究对比了印度可及的九种仿制L-门冬酰胺酶与创新药。
- 纳入195例ALL患儿诱导期给予10000 IU/m2后测定72小时谷浓度活性,共240份样本。
- 体外分析评估三种仿制药的标示量活性,并用LC/MS检测宿主污染蛋白。
主要发现
- 各仿制药品牌分析样本数7~66份(中位18份),创新药7份。
- 仿制药未达预设临床阈值活性50 IU/L的比例从16.7%(2/12)至84.9%(28/33)不等。
- 创新药所有样本活性均大于50 IU/L。
- 三种仿制药体外活性为标示量(10000 IU)的71.4%~74.6%,创新药为93.5%。
- 仿制药5经LC/MS鉴定出25种宿主污染蛋白,相对肽段计数占总肽段的27.1%。
关键数值与推荐
- 预设临床阈值活性为50 IU/L。
- 给药剂量为10000 IU/m2。
- 谷浓度测定时间为给药后72小时。
临床怎么用
- 临床使用仿制L-门冬酰胺酶时应警惕活性不足风险。
- 建议开展治疗药物监测并结合剂量调整策略以确保疗效。
局限性
- 样本来自单一国家(印度)的仿制药,外推需谨慎。
- 创新药样本量较少(7份),对比可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: L-asparaginase is an essential medicine in the treatment of pediatric acute lymphoblastic leukemia (ALL) and the quality of generic formulations is an area of concern. We compared nine generic formulations of L-asparaginase available in India with the innovator. METHODS: The quality of formulations was assessed by measuring 72-hour trough asparaginase activity in children with ALL during induction following administration of 10,000 IU/m2 of L-asparaginase. In-vitro analysis of the label claim was assessed by measuring activity of three generic formulations. Liquid chromatography-mass spectrometry (LC/MS) was used to determine the amount of host contaminant proteins (HCPs) in the formulations. RESULTS: Between March 2015 to June 2018, 240 samples from 195 patients were analyzed. The number of samples analyzed ranged from 7-66 per generic brand (median: 18) and seven of the innovator. The proportion of generic formulations that failed to achieve a predefined clinical threshold activity of 50 IU/L ranged from 16.7% (2/12) to 84.9% (28/33) in the highest activity to lowest activity generic respectively. On other hand, all innovator samples had activity greater than 50 IU/L. In-vitro asparaginase activity in the three generic formulations tested ranged from 71.4-74.6% of the label claim (10,000 IU) compared to 93.5% for the innovator. LC/MS analysis of generic 5 identified 25 HCPs with a relative peptide count of 27.1% of the total peptides. CONCLUSIONS: Generic formulations had lower asparaginase activity which raises serious clinical concerns regarding their quality. Until stringent regulatory enforcement improves the quality of these generics, dose adaptive strategies coupled with therapeutic drug monitoring need to be considered.
引用
- Sankaran H, Sengupta S, Purohit V, et al. A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia. Br J Clin Pharmacol. 2020. PMID: 31925802. doi:10.1111/bcp.14216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。